FDA Inspection 1196117 — Triumph Pharmaceuticals Inc.

Triumph Pharmaceuticals Inc. — FEI 3014539253

The FDA completed an inspection of Triumph Pharmaceuticals Inc. on January 19, 2023 in Saint Louis, MO. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 5 citations were issued during this inspection. Product area: Devices.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
January 19, 2023
Fiscal Year
2023
Product Type
Devices
Project Area
Postmarket Assurance: Devices
Location
Saint Louis, MO (United States)

Citations

IDCFRDescription
1471321 CFR 820.198(a)Lack of or inadequate complaint procedures
313021 CFR 820.100(a)Lack of or inadequate procedures
333121 CFR 820.181DMR - not or inadequately maintained
342621 CFR 820.50(a)(1)Documented evaluation
63021 CFR 803.17Lack of Written MDR Procedures